Top 5 Contagion® News Articles for the Week of August 20, 2017
AUG 26, 2017 | CONTAGION® EDITORIAL STAFF
#5: Proton Pump Inhibitors Present Real Risks to People Living with HIV
The HIV-positive subjects with a history of PPI use did tend to be older (59.6 years) than those who had not taken PPIs (54.3 years), and the researchers were careful to address this disparity in their methods. “Age is a known driver of immune activation,” Jose Serpa-Alvarez, MD, MS, an assistant professor of medicine and director of the Infectious Diseases Fellowship program at Baylor College of Medicine, and the study’s lead author, told Contagion ®. “Although subjects on chronic PPIs were older than those not taking PPIs, we controlled for this variable in our multivariate model. The use of PPIs was still significantly associated with higher levels of sCD14, a marker of innate immune activation.”
Should clinicians advise patients with HIV to avoid taking PPIs at all costs? “At this point in time, there is not enough evidence to advise immediate discontinuation of PPIs,” Dr. Serpa-Alvarez told Contagion ®. “However, we think it would be prudent to use them only when strictly indicated and for short periods of time. These recommendations are valid for all people but especially for those living with HIV.”
Read more about the use of PPIs in people living with HIV, here.
#4: Dalbavancin For Treatment of MRSA Pneumonia
In an article published in the Journal of Pharmacology and Pharmacotherapeutics, Katie E. Barber, PharmD, from the University of Mississippi, Jackson, and colleagues report a case of a HIV-positive 28-year-old man with pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) who was treated with dalbavancin.
“This case is unique because it is the first reported use of dalbavancin for MRSA pneumonia,” the authors write.
Although pneumonia is one of the most common infectious diseases, MRSA pneumonia is uncommon. Nevertheless, clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society recommend that clinicians provide antibiotic coverage for MRSA in patients with health care-associated and ventilator-associated pneumonia.
Continue reading about the use of dalbavancin against MRSA pneumonia, here.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512